Trial Outcomes

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

The study tested an ATR inhibitor with Imfinzi in patients whose disease progressed after immunotherapy plus platinum chemotherapy.